VeraMorph is a specialty pharmaceutical start-up spun out of MIT and structured around development of a polymer-based oral dosage technology to improve the therapeutic index of poorly soluble small molecules. Working with Dupont personnel, Veramorph is leveraging an advanced proprietary hydrogel based oral drug delivery platform that enables larger pharmaceutical companies to improve the performance of their products and reduce the cost and time to bring them to market.The smaller firm's lead capability - DPODs - Disintegrating Pre-formed Oral Dosages - is designed to create an optimal combination of high drug stability, fast dissolution rate, and prolonged levels of high supersaturation in an oral dosage form capable of higher drug loading than current formulations. In addition to directly interacting with DuPont experts, both MCET and Veramorph are awarded as part of the FastPass up to 1 year of free access to the capabilities of the Delaware Innovation Space. This includes turnkey wet laboratory and office spaces, access to a wide range of high-end chemistry and biotech scientific equipment, strategic business development, technical and fundraising programming tailored to the specific needs of each startup.
